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ABSTRACT Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by progressive sino-
pulmonary disease, with symptoms starting soon after birth. A European Respiratory Society (ERS) Task
Force aims to address disparities in diagnostics across Europe by providing evidence-based clinical practice
guidelines. We aimed to identify challenges faced by patients when referred for PCD diagnostic testing.
A patient survey was developed by patient representatives and healthcare specialists to capture
experience. Online versions of the survey were translated into nine languages and completed in 25
countries. Of the respondents (n=365), 74% were PCD-positive, 5% PCD-negative and 21% PCD-
uncertain/inconclusive. We then interviewed 20 parents/patients. Transcripts were analysed thematically.
35% of respondents visited their doctor more than 40 times with PCD-related symptoms prior to
diagnostic referral. Furthermore, the most prominent theme among interviewees was a lack of PCD
awareness among medical practitioners and failure to take past history into account, leading to delayed
diagnosis. Patients also highlighted the need for improved reporting of results and a solution to the
“inconclusive” diagnostic status.
These findings will be used to advise the ERS Task Force guidelines for diagnosing PCD, and should
help stakeholders responsible for improving existing services and expanding provision for diagnosis of this
rare disease.
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Introduction
Primary ciliary dyskinesia (PCD) is a rare heterogeneous condition. Genetic mutations cause abnormal
ciliary function which is associated with abnormal ciliary ultrastructure in 70% of cases [1, 2]. PCD is
characterised by impaired mucociliary clearance of upper and lower airways. Symptoms usually present
soon after birth and range in severity from mild transient tachypnoea to significant neonatal respiratory
failure requiring prolonged respiratory support [3–5]. Chronic and progressive chest symptoms persist
throughout life, and include daily wet cough and recurrent chest infections which almost consistently lead
to bronchiectasis [3]. Upper airway symptoms include rhinosinusitis and recurrent serous otitis media
with hearing impairment [6]. Situs inversus is seen in approximately 40% of cases and situs ambiguous is
seen in approximately 10% of cases [5].
Reported prevalence varies from 1:2000 to 1:40000, which could be due to a true variability across
demographics but is likely to reflect differences in access to diagnostic facilities [7–9]. A European Respiratory
Society (ERS) Task Force survey of 26 European countries found that PCD is underdiagnosed or diagnosed
late, particularly in countries with low healthcare expenditure [10]. In addition to improving respiratory
prognosis [11–13], early diagnosis also facilitates appropriate management of the associated upper airway
disease since management is different to non-PCD-related serous otitis media and sinusitis [14]. Diagnosis
also allows genetic counselling for the family.
There is no “gold standard” test to diagnose PCD and diagnostic pathways vary between/within countries
[15–17]. European guidelines recommend that PCD should be confirmed in a specialist centre using
appropriate diagnostic testing [18]. PCD diagnostic investigations are complex, requiring expensive
infrastructure, and an experienced team of clinicians, scientists and microscopists. Due to inadequate
samples or inadequate results, several samples may need to be taken until a conclusive result is achieved
and the time until a conclusive result is reached can vary greatly between patients [16, 19, 20]. Various
models exist to deliver diagnostic services for this rare disease, generally with a network of satellite
screening centres accessing a specialist centre [20–22].
An ERS Task Force (TF-2014-04) was established in September 2014 to develop clinical practice guidelines
on diagnosing or refuting the diagnosis of PCD. An important element to consider in developing practice
guidelines is the patient perspective and experiences of the diagnostic process. There has been no previous
international research evaluating PCD patients’ experiences and their perspective on the diagnostic
process. This study was therefore undertaken to address this gap and to inform the Task Force.
Over 25 years ago the authors of a pioneering study to characterise PCD concluded “all children with
unexplained chronic respiratory disease, in particular those with symptoms starting in the perinatal period,
should be investigated for ciliary dyskinesia” [23]. However, access of patients with these symptoms to
diagnostic services remains problematic.
The present study used a mixed-methods (qualitative and quantitative) approach to more fully understand
the perspectives of patients, and to identify the most prominent issues and concerns arising for patients at
any stage in the diagnostic pathway.
Methods
The study combined an international web-based survey and semi-structured interviews, ensuring both
breadth and depth. Ethical approval for semi-structured interviews was provided by Southampton and
South West Hampshire Research Ethics Committee (A 07/Q1702/109). Audio-recorded and/or written
consent was obtained from interviewees and electronic consent recorded for survey participants.
We conducted an international survey to investigate the patients’ perspectives on diagnosis between June
and November 2014. We designed the survey based on findings and expertise from three sources: 1)
semi-structured interviews with patients from a previous study to understand factors impacting on quality
of life in patients with PCD [24]; 2) consultation with patient representatives in the UK, USA and
Switzerland; and 3) consultation with the European Lung Foundation (ELF). Survey topics included
measures of demographics, age of diagnosis, methods of diagnosis, the patient opinions on their diagnostic
experience and how diagnostic services should be delivered (box 1). To ensure it reflected wider
international issues, the prototype survey was amended by ERS Task Force panel members from seven
countries (UK, France, Switzerland, Germany, Italy, Ireland and Belgium). The finalised online survey
(available in the online supplementary material) was translated into nine European languages (Italian,
Polish, Russian, Portuguese, Czech, Dutch, German, French and Greek) using forward and back
translations. We aimed to include all European countries by highlighting the study to clinicians through
the ELF. Links to the survey were distributed by patient organisations, clinicians of the ERS Task Force
and the ELF via newsletters, targeted emailing and social media channels. The survey was hosted by
University of Southampton (www.isurvey.soton.ac.uk).
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The survey sought the opinions of patients with PCD and parents of children with PCD. We also sought
the opinions of all patients who had been considered for PCD testing irrespective of their diagnostic
outcome, i.e. positive/negative/inconclusive, or by their diagnostic protocol and the tests that they received
if any, i.e. nasal nitric oxide (nNO), transmission electron microscopy (TEM), high-speed video
microscopy (HSVM), genetic, immunofluorescence or diagnosis based on symptoms, etc.
The survey was anonymous; however, respondents were invited to provide their email address if they
wished to take part in a telephone interview. Over 80 participants provided their email address and
expressed interest to be interviewed. 20 of these respondents were recruited. Efforts were made to ensure
participants spoke English, and represented different age groups, diagnostic status and countries. The
semi-structured interviews were conducted by the lead author (L.B.) who is trained and experienced in
semi-structured/open-ended interviews and qualitative analyses, and has knowledge of PCD having
developed patient-reported outcome measures for PCD (QOL-PCD [24]). Topics of discussion included:
when they first heard of PCD, medical providers seen, experience with diagnostic services and any
problems encountered. Telephone interviews were used to ensure a geographical representation, to provide
a degree of anonymity and to relieve pressure on participants to provide the socially acceptable answer [25],
i.e. discussing challenges experienced with diagnostic services and medical professionals.
Data analysis
We used simple descriptive statistics to investigate comparisons of the demographic characteristics across
the range of diagnostic outcomes and between countries. Data were checked for normality and two-tailed
parametric (t-test) or nonparametric (Mann–Whitney) tests were used to assess differences among mean
and median values for the group as a whole and across each diagnostic outcome. Positively skewed data
were transformed, where appropriate, prior to performing statistical analysis. Categorical variables were
presented by frequency and percentage. Statistical analyses were performed with SPSS Statistics for
Windows version 21.0 (IBM, Armonk, NY, USA).
Semi-structured interviews were recorded, transcribed, verified for accuracy and identifying information was
removed. In order to maintain thoroughness, a COREQ checklist was used throughout the study [26]. Notes
were maintained at all times to track decisions and help to verify the link between the original data and the
findings [26]. Thematic analysis was used where patterns within data were identified using an inductive or
“bottom-up” approach. By using an inductive approach, the themes identified were strongly linked to the
data themselves [27]. The interview transcripts were single-coded by L.B. Themes and subthemes were
discussed with the senior author J.S.L. in order to confirm the validity of the interpretations that were being
developed. Data was coded using NVivo qualitative data analysis software version 10 (QSR International,
Doncaster, Victoria, Australia). Recruitment ceased once saturation was reached. Themes and subthemes
were presented in three stages: pre-diagnosis, diagnosis and post-diagnosis (figure 1).
Results
Study population
The survey was completed in nine European languages by 365 participants from 25 countries. The
majority of respondents had been diagnosed with PCD (74.3%), with a smaller percentage of respondents
distributed across other diagnostic outcome groups. 54.5% of the respondents were parents of children and
41.6% were adults who had been tested for PCD. 49.8% of PCD-positive respondents had situs inversus
and 11.8% were born with a cardiac defect. Only one (6%) of the PCD-negative respondents had situs
inversus and 0% had a cardiac defect (table 1). Respondents were resident in Germany (21%), the USA
(18%), France (15%), the UK (13%), Belgium (11%), Denmark (5%) and others (17%, including Italy,
BOX 1 Survey topics: the survey allowed participants to rate the importance of topics relating
to their diagnostic experience
• The ability to meet, discuss and have their samples analysed by primary ciliary dyskinesia experts
• Repeat testing for inconclusive results
• The availability of information before testing
• The availability of information after diagnosis
• Travelling long distances for diagnostic testing
• The level of agreement on whether their condition, treatment and quality of life had improved since
diagnosis
• A free text option to allow for comments was provided at the end of the survey
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Australia, Switzerland, Canada, Cyprus, Ireland, Greece, South Africa, Austria, Chile, Portugal, Qatar,
Poland, Iran, Norway, Spain, Portugal and Algeria).
Semi-structured interviews were conducted with 20 participants from seven countries (40% from the UK)
and were diverse in age group, diagnostic testing and diagnostic outcomes (25% were negative/inconclusive/
still waiting). 25% were parents of children aged 0–4 years, 35% were parents of children aged 5–17 years
and 40% were patients tested at 18 years or older. The majority (70%) were from English-speaking
countries (online supplementary table S1). Saturation was reached after the 14th interview.
Lack of awareness and 
attitudes among medical 
professionals led to 
delayed diagnosis
Pre-diagnosis:
journey to referral
Symptoms not taken seriously
Past medical history not
considered during consultation
Older patients treated without
investigation for route cause of
COPD, bronchiectasis, etc.
Testing in a PCD 
diagnostic centre was a 
positive experience
Diagnosis:
experience of diagnostic
testing
Age-specific experiences
Communication of test
results
Information provided on PCD
Communication for testing
Children found nasal scraping
distressing
Importance of discussing
results with a PCD expert
Problematic when results were 
fed back in stages without an 
overall report
Emotional response to a
positive diagnosis
Post-diagnosis
impact of diagnosis
Challenges associated
with an inconclusive
outcome
Treatment burden
Relief, i.e. having a label,
condition taken seriously
Distress, i.e. diagnosis not made 
sooner
Improvement to health was
patient specific
Credibility, e.g. medical
professional, insurance
Excluded from search
FIGURE 1 Themes and subthemes from semi-structured interviews, presented in three stages: pre-diagnosis,
diagnosis and post-diagnosis. COPD: chronic obstructive pulmonary disease; PCD: primary ciliary dyskinesia.
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Pre-diagnosis: journey to referral
Most survey respondents had repeatedly visited medical professionals with PCD-related symptoms prior to
referral; 37% of positive patients had more than 40 visits and only 3% had been referred soon after birth. 61% of
PCD-negative respondents had 20 or less visits prior to referral for testing. 76.4% of respondents were older
than 1 year of age when they were tested for PCD. The overall median (interquartile range) age at testing was
6 (11) years (table 2). The mean age at testing was slightly younger for those with situs inversus (mean
2.38±2.04 versus 2.97±1.76 for those without, p=0.016) and congenital cardiac defect (mean 2.01±1.78 versus
2.76±1.91 for those without, p=0.036). The most common reasons for diagnostic referral of interviewees was an
episode(s) of pneumonia, i.e. radiography and computed tomography scan showing changes (six of 20), and
self-referral following reading about PCD online (three of 20).
Interviewees attributed a delay in referral for diagnostic testing to a lack of awareness and a poor attitude
among healthcare professionals (14 of 20) (figure 1). 11 of 12 parents reported that their child had respiratory
distress at birth but eight of 11 were not referred until repeated visits to their physicians, sometimes over
many years. Participants felt that the underlying cause of symptoms was not considered nor was past medical
history taken into account. Adult participants felt they were not taken seriously, while parents reported being
treated as over-cautious and over-protective. Many participants were continually treated for other common
conditions, e.g. asthma and hay fever, despite treatments not having any effect. (box 2: A–D). Older
participants (over 30 years at diagnosis) felt the cause of their illness was not seen as a priority for
investigation due to their age with focus instead being on the treatment of chronic obstructive pulmonary
disease (COPD)/bronchiectasis (box 2: A and B). 99% of survey respondents felt that an improvement in PCD
awareness amongst general practitioners and local doctors is needed to encourage early referral (figure 2).
Diagnosis: experience and impact of diagnostic testing
The most common diagnostic procedures experienced by survey respondents were nasal scraping (79%),
nNO testing (44%) and genetic testing (37%). 88% of survey participants rated it as important to have
multiple tests if this ensured an accurate result and to see a PCD expert even if it means travelling long
distances (figure 2). This was echoed overall in the interviews (box 3: A–C); however, some age-specific
variances emerged with parents describing nasal scraping as a moderately distressing experience. This
distress was heightened if their child needed a repeat brushing (box 3: B and C). Participants reported that
testing was carried out in an efficient and empathetic manner with the appropriate amount of information
provided once they reached specialist services (eight of 20) (box 3: D and E).
TABLE 1 Characteristics of participants in the survey stratified by primary ciliary dyskinesia (PCD) disease status
Total PCD disease status
Positive Negative Inconclusive Other#
Subjects 365 (100) 271 (74.3) 18 (4.9) 29 (8.0) 47 (12.9)
Respondent’s status
Patient tested for PCD 152 (41.6) 115 (42.4) 8 (44.4) 8 (27.6) 21 (44.7)
Parent of child tested for PCD 199 (54.5) 152 (56.1) 10 (55.6) 21 (72.4) 16 (34.0)
Missing 14 (3.8) 4 (1.5) 10 (21.2)
Sex
Male 156 (42.7) 114 (42.1) 8 (44.4) 14 (48.3) 20 (42.6)
Female 195 (53.4) 154 (56.8) 7 (38.9) 14 (48.3) 21 (44.7)
Missing 14 (3.8) 3 (1.1) 3 (16.7) 1 (3.5) 6 (12.8)
Age of suspected PCD patient at time of survey years
<5 54 (14.8) 38 (14.0) 2 (11.1) 8 (27.6) 6 (12.8)
5–12 88 (24.1) 61 (22.5) 7 (38.9) 10 (34.5) 10 (21.2)
13–17 52 (14.3) 42 (15.5) 1 (5.6) 4 (13.8) 5 (10.6)
18–35 70 (19.18) 58 (21.4) 3 (16.67) 2 (6.9) 7 (14.9)
36–50 52 (14.25) 45 (16.61) 2 (6.9) 5 (10.6)
51–65 26 (7.12) 19 (7.01) 1 (5.56) 1 (3.45) 5 (10.6)
>65 11 (3.01) 4 (1.48) 4 (22.22) 2 (6.9) 1 (2.1)
Missing 12 (3.29) 4 (1.48) 8 (17.0)
Situs inversus 157 (43.0) 135 (49.8) 1 (5.6) 6 (20.7) 15 (31.9)
Congenital heart defect 41 (11.2) 32 (11.8) 4 (13.8) 5 (10.6)
Data are presented as n (%). #: other includes participants still waiting for results and those who received a false-positive result as well as
missing values.
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Diagnosis: awaiting and receiving results
A total of 67% of survey respondents received their result within a 6 months period and 12% reported that
they received confirmatory results within 1 week of testing (table 2). Opinions varied on what was deemed
to be a “long time” to wait for results (box 4: A and B). 94% of survey participants rated having samples
analysed by a PCD expert as important or very important and 97% rated having the opportunity to
discuss results with a PCD expert as important or very important (figure 2).
Participants referred to encountering problems when results for tests such as TEM and genetics were
received much later than others, e.g. HSVM and nNO test. Explanations of what the results mean in
combination were incorrectly relayed back to the patients. To overcome this, participants recommended
that it would be helpful if they could receive an overall report explaining what the results mean in
combination and to have the opportunity to discuss this with a PCD expert (box 4: D and E).
Post-diagnosis: impact of diagnosis
Participants who experienced an inconclusive diagnostic result discussed the practical constraints of such
an outcome, e.g. insurance constraints and not being included in research (box 5: A and B). The
emotional impact of a positive diagnosis was described by many as leading to a profound sense of
validation that their symptoms were down to a specific named condition (box 5: C and D). Participants
also reported feeling some distress that their/their child’s diagnosis process took such a long time and felt
that an earlier diagnosis could have made a significant difference to the state of their current and future
health; relief was expressed once they had a label and could pursue getting the correct treatment (box 5: E
and F). Relief was also described when a negative diagnosis was received (box 5: G).
TABLE 2 Age at testing, time taken to receive test results and number of visits to doctor before referral stratified by primary
ciliary dyskinesia (PCD) status for survey participants
Total PCD disease status
Positive Negative Inconclusive Other#
Subjects 365 (100) 271 (74.3) 18 (4.9) 29 (8.0) 47 (12.9)
Age at initial testing years¶
<1 42 (11.5) 30 (11.1) 4 (13.8) 8 (17.0)
⩾1 279 (76.4) 229 (84.5) 14 (77.8) 20 (69.0) 16 (34.0)
Missing 44 (12.1) 12 (4.4) 4 (22.2) 5 (17.2) 23 (48.9)
Visits to doctor before diagnosis
Referred soon after birth 12 (3.3) 9 (3.3) 2 (6.9) 1 (2.1)
1–10 64 (17.5) 46 (17.0) 6 (33.3) 5 (17.3) 7 (14.2)
11–20 56 (15.3) 45 (16.6) 5 (27.8) 3 (10.3) 3 (6.4)
21–40 68 (18.6) 52 (19.2) 4 (22.2) 8 (27.6) 4 (8.5)
>40 123 (33.7) 101 (37.3) 1 (5.6) 8 (27.6) 13 (27.7)
Other 22 (6.03) 13 (4.8) 1 (5.6) 3 (10.3) 5 (10.6)
Time to diagnosis after testing for PCD
<1 week 45 (12.3) 39 (14.4) 1 (5.6) 1 (3.5) 4 (8.5)
1–4 weeks 76 (20.8) 61 (22.5) 8 (44.4) 3 (10.3) 4 (8.5)
1–6 months 122 (33.4) 105 (38.8) 8 (44.4) 4 (13.8) 5 (10.6)
6–12 months 10 (2.7) 8 (3.0) 1 (3.5) 1 (2.1)
>1 year 28 (7.7) 24 (8.9) 1 (5.6) 2 (6.9) 1 (2.1)
Still waiting 28 (7.7) 15 (51.7) 13 (27.7)
Not sure 36 (9.9) 31 (11.4) 2 (6.9) 3 (6.4)
Missing 20 (5.5) 3 (1.1) 1 (3.5) 16 (34.0)
Diagnostic procedures
Nasal nitric oxide 157 (43.0) 110 (40.6) 14 (77.8) 17 (58.6) 16 (34.0)
Nasal scraping 283 (77.5) 221 (81.6) 16 (88.9) 28 (96.6) 18 (38.3)
Bronchoscopy 134 (36.7) 102 (37.6) 6 (33.3) 12 (41.4) 14 (29.8)
Genetics 134 (36.7) 105 (38.8) 1 (5.6) 13 (44.8) 15 (31.9)
Saccharine test 19 (5.2) 14 (5.2) 1 (5.6) 2 (6.9) 2 (4.3)
Nuclear medicine scan (e.g. MRI and CT scans) 25 (6.9) 19 (7.0) 2 (11.1) 1 (3.5) 3 (6.4)
Radiography or CT scan alone 8 (2.2) 2 (0.7) 6 (12.8)
Symptoms only 12 (3.3) 6 (2.2) 6 (12.8)
Data are presented as n (%). MRI: magnetic resonance imaging; CT: computed tomography. #: other includes participants still waiting for
results and those who received a false-positive result as well as missing value; ¶: median age (interquartile range) 6 (11) years (n=226).
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Post-diagnosis: follow-up care and support available
Participants expressed a sense of being overwhelmed by the prescription of medication, treatments and
clinic appointments following a positive diagnosis, particularly when newly diagnosed. The benefits of a
diagnosis to the reported current state of health varied among survey participants with 21% reporting no
improvement to health since diagnosis (figure 2). A significant difference was found between those who
were diagnosed in childhood (0–12 years) and those who were diagnosed in adolescence/adulthood (over
13 years) on the level of agreement that health has improved since diagnosis (p=0.041). Similar variability
was found among the interviewees with some participants feeling that their/their child’s health had
benefited greatly since starting treatments (box 5: A–C) and others reporting no major change since
diagnosis despite adhering to the prescribed treatments (box 5: D).
In the survey, 91% of respondents strongly agreed/agreed that it is important to have a patient
organisation in each country (figure 2). The role of PCD patient support groups following referral was
further elaborated in the interviews as important in terms of meeting other families affected by PCD and
having an opportunity to share experiences (box 6: E and F). Participants in countries without a PCD
support group spoke of the need for support services enabling discussions about experiences specific to
their country’s health system and in their native language (box 6: G–I).
BOX 2 Subthemes and participant quotes for pre-diagnostic testing: journey to referral
Past medical history was not considered
A It was a wait, but it was more the fact that no-one was looking at the history … she’d been in neonatal
for eleven days when she was born, she was full-term … she couldn’t get her sats up … how many
times I’d been in, you know and no one put two and two together. [Participant 010, parent, positive PCD]
Symptoms not taken seriously: parents treated as fussy/over protective
B … and all this time you know … time’s going on … I don’t think that I was listened to as a mum, it was
a bit like, I was you know maybe of over worrying, things like that. [Participant 004, parent, positive
PCD]
C I think the lateness in the diagnosis has caused the bronchiectasis and … other problems and I think
that could have been prevented if someone would have taken me a bit more seriously. [Participant 010,
parent, positive PCD]
Mistreated for other illnesses
D … he treated her for asthma, but the picture never made sense, and she didn’t look like an asthmatic
child. [Participant 015, parent, positive PCD]
Older patient treated without investigation for route cause
E There seems to be, among pneumologists, that they think in adult people or at least people who are
more than forty years old, it doesn’t matter anymore which is the reason for this COPD, and they don’t
even think about testing it. [Participant 011, adult, positive PCD]
PCD: primary ciliary dyskinesia.
Per cent
Being able to see a specialist in PCD is important, even if long 
distance travelling is necessary
It is better to have more than one test if it ensures the result 
is more accurate
It is important  to have samples analysed by scientists with 
expertise in PCD
It is important to discuss test results with a PCD expert
It is important to see a doctor with specialist knowledge of 
treating PCD
Patient organisations in all countries to support patients 
is important
Improving awareness of PCD among GPs/local doctors to 
encourage early referral is important
Since diagnosis, health has improved
30 4020100 50 60 80 9070 100
Strongly agree
Agree
61.30
26.51
64.47
77.97
81.87
82.30
64.37
87.82 11.05
26.15 6.04
16.29
16.15
16.10 4.24
23.78 8.31
24.90 21.28 14.86
27.40 6.79
Neutral
Disagree
Strongly disagree
Don’t know
FIGURE 2 Survey findings on patient opinion of diagnostic effect on health and the importance of expert service provision. PCD: primary ciliary
dyskinesia; GP: general practitioner.
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Discussion
This study represents findings from an international survey and in-depth semi-structured interviews
specifically designed to understand the experiences, concerns and needs of patients requiring diagnostic
testing for PCD. It describes the experiences and perspectives of 365 adult patients and parents from 25
European Union (EU) and non-EU countries, 20 of whom were interviewed to obtain an in-depth insight
to their experiences and opinions of being tested for PCD.
When discussing the journey to referral, the overarching theme was the lack of PCD awareness by medical
professionals thus leading to a delayed diagnosis. This was also reflected in the survey, with 34% of the
total respondents reporting that they visited their doctor on more than 40 occasions for PCD-related
symptoms before PCD was considered a possible diagnosis. There is a clear need to reiterate to nonexpert
clinicians the guidelines [23] published a quarter of a century ago, which stated that individuals with
chronic upper and lower airway symptoms should be investigated for PCD. Previous research has found a
sense of isolation and mistrust in medical care among PCD patients which is heightened by a lack of PCD
awareness by the patient’s general practitioner [28]. Participants were concerned that delayed diagnosis
had adversely affected their health. All adult interviewees were diagnosed late in life (over 30 years of age)
and felt that their current state of health might have been better had they been diagnosed earlier. This
BOX 3 Subthemes and participant quotes for diagnosis: experience and impact of diagnostic
testing
Importance of meeting a PCD expert to be tested and to discuss results
A And everything just went really smooth for us when we were over there. Having to go over there, it
wasn’t great, but you know it’s the facilities are not in Ireland, so you just have to do it. [Participant
003, parent, inconclusive PCD]
Distress from nasal scrape
B … it’s a little bit distressing for parents … it’s got to be done … you know you’re holding a child still
and you don’t want to do it, but you have to, for their best. [Participant 004, parent, positive PCD]
C It was a bit uncomfortable … I mean I don’t think she was expecting it to be quite as uncomfortable as
it was, but having said that she went along with it okay, she knew she had to get it done. [Participant
002, parent, positive PCD]
Communication of testing procedure
D First of all it was an absolutely painless experience and the people doing it explained it so well, I
wouldn’t change a thing at all. [Participant 001, adult, positive PCD]
E I mean it’s all very new for me … but … the amount of information that I got … which explained the
process and explained what was being done and how it was going to be achieved, I think was very well
done, and the staff involved were very empathetic, very sympathetic. [Participant 008, adult, inconclusive
PCD]
PCD: primary ciliary dyskinesia.
BOX 4 Subthemes and participant quotes for diagnosis: awaiting and receiving results
Long-time taken to receive results
A I had to ring up months after, chasing up the results … we should have got the results sooner than
what we did … like the testing was done in the January and probably should have got the results
probably March, April. Ended up being like June, July, because I had to actually chase up myself to
get the results. [Participant 019, parent, positive PCD]
B No, definitely a month is a long time to wait. To know what’s wrong with your child or significant other
or something, but it takes as long as it takes; I have gotten used to that. [Participant 017, parent, positive
PCD]
Experience of communication of diagnostic results
C And I got the results, let’s say in drops, maybe one year later I got the information about the electron
microscopy was or maybe it was eighteen months later. [Participant 011, adult, positive PCD]
D I got the information from my doctor that my son … probably has PCD … the cilia didn’t move … about
already 1 month later … the report that the electron microscopy was normal, and the report from the
electron microscopy said we cannot prove primary ciliary dyskinesia based on this. The doctor told
me, “well then it’s not primary ciliary dyskinesia”. [Survey participant, open text response]
E Before they did any testing we had a good discussion about what it was and what it meant, and then
when we got the results they explained what it was that wasn’t working … It’s usually better if
somebody talks to you rather than it being written down. [Participant 010, parent, positive PCD]
PCD: primary ciliary dyskinesia.
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finding supports previous research that found that delayed PCD diagnosis led to poorer subsequent quality
of life [29]. To prevent a delayed diagnosis, participants felt that medical professionals need be to be better
informed about PCD, its signs and symptoms, and relevance of past medical history. It is hoped that
increased availability of screening tools such as nNO [30] and clinical prediction rules (e.g. PICADAR)
[31, 32] will increase identification of appropriate patients for diagnostic testing and reduce delays.
However, if the screening tools are used in patient populations with a low likelihood of PCD there is a risk
that excessive numbers of patients will be referred to specialist services, resulting in unnecessary testing for
low-risk patients whilst overwhelming diagnostic centres [33].
When receiving a diagnosis, patient and parent interviewees who visited specialised diagnostic centres were
satisfied with their experience. The implications of normal electron microscopy wrongly being interpreted
as negative diagnosis [17] by non-PCD experts was highlighted. Respondents felt that being able to discuss
their test results with a PCD expert as well as receiving a written report of all test results was important,
and contributed to a sense of certainty and assurance.
Due to the importance of societal, health and cultural differences between countries, we aimed to recruit
participants from diverse geographical regions. We first examined the results from all participants and
then analysed countries separately. A quantitative comparison of countries grouped by general government
expenditure on health (the sum of outlays for health maintenance, restoration or enhancement paid for by
government entities) or grouped by countries with and without specialist diagnostic services was prevented
due to the limited numbers of respondents from some areas. We have, however, included the analyses
from the UK, Germany and the USA to show comparisons with differing approaches to delivery of
diagnostic services and availability of tests. The percentage of respondents who had 40 or more visits to
their doctor with symptoms related to PCD before being referred for testing was significantly higher in the
USA (44%) compared with the UK (24%) and Germany (35%) (online supplementary table S2). The
interviews also revealed country-specific variances. Participants from non-English-speaking countries
strongly advocated that support groups be set up in their country and for information to be available
online in all languages. The inconclusive PCD diagnosis also had country-specific implications, with
participants from countries including the USA requiring a definitive diagnosis in order to access insurance
BOX 5 Subthemes and participant quotes for post-diagnosis: impact of diagnosis
Impact of an inconclusive diagnostic result
A I have suffered from serious upper and lower respiratory infections all my life. I have an “inconclusive”
status re: diagnosis of PCD … there must be a category of PCD that includes a variant of PCD as a
diagnostic category. This is crucial for people who have insurance challenges. [Survey participant, open
text response]
B I hate the probable PCD diagnosis. Four years ago my three kids were given that. All classic
symptoms with bronchiectasis and low nasal nNO. But cilia appeared normal. It infuriates me they
can’t be included in research. [Survey participant, open text response]
Emotional response to positive diagnosis: feeling of validation
C Like to have the confirmed diagnosis … well I am just really excited they were finally able to prove it’s
not in my head. You know like I didn’t make it up. [Participant 016, adult, positive PCD]
D I actually felt like shouting Alleluia once she was diagnosed, because it was just years and years of
worry and thinking what’s going on and why, and I just, you kind of doubt yourself as a mum.
[Participant 010, parent, positive PCD]
Emotional response to positive diagnosis: relief but a sense of sadness that diagnosis was not sooner
E You know that’s kind of like oh wow, finally I’m no longer a book-case. But then I have all this damage
that you know at least, you know at least I have a diagnosis, twenty years later, but it’s a little late.
[Participant 009, adult, positive PCD]
F Well it was a certain relief, first of all in that you know we can explain now … we can help her in the
way that she needs. So really it was just a huge kind of relief really, just knowing that we have an
explanation now. Along with you know a bit of sadness that we didn’t catch onto it earlier. [Participant
002, parent, positive PCD]
Impact of a negative diagnosis: relief
G I was very relieved of course. I didn’t know anything at all about it until I was told by the consultant I
was going to be sent for the test. And then I received some documentation in advance with the
appointment. And I also read a little bit about it online … I was quite concerned, because one of the
things I heard was that it could affect your hearing and you can go deaf … I was quite anxious, so the
length of time being referred and actually having the tests, I was very worried. [Participant 007, adult,
negative PCD]
PCD: primary ciliary dyskinesia.
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for treatments. A resolution to the problems associated with an inconclusive result or a “probable” PCD
diagnosis was called for.
Strengths and limitations
This is the first international study of the perspective of patients referred for PCD diagnostic testing.
Questions for the survey involved the contribution of an international panel of PCD experts and patient
representatives. However, our study does have limitations: response varies from country to country, with
the main percentage of respondents from countries with established diagnostic centres, i.e. the UK, USA,
Germany and France.
The survey also aimed to include patients who were referred and still waiting for results, who were
negative for PCD, or who have been found to be inconclusive for PCD and are still going through testing;
however, 74.3% of survey respondents were PCD-positive, with PCD-negative representing only 4.9%,
inconclusive 8% and still waiting 3%. It is especially low considering between 11.5% and 18.6% of referrals
are eventually diagnosed with PCD [17, 31–33]. It is perhaps not surprising that patients with ongoing
interest in the disease (PCD-positive) were more likely to respond to the survey. This limits our capacity to
assess the perspective of the population with an inconclusive or negative outcome.
Although participants were asked about the tests that had been performed, their results cannot be verified
and there is therefore diagnostic uncertainty. In addition, a number of participants’ diagnoses were based
on tests that are not considered robust, e.g. the saccharine test. It is therefore likely that some patients may
have been diagnosed who do not have PCD and vice versa. Since we were interested in the experiences and
outcomes of patients from diverse clinical settings it was important to include groups where diagnostic
BOX 6 Subthemes and participant quotes for post-diagnosis: follow-up care and support
available
Treatment burden and effect on condition
A It was a bit of a shock … I was probably in my mid-thirties then, to suddenly be told, right, you’ve got
to do twenty minutes of physio twice a day, you’ve got to take this blue puffer, and the brown puffer …
as soon as you get a chest infection you’ve got to take really strong antibiotics, I rebelled against that,
just because it was too much all at once. [Participant 006, adult, positive PCD]
B For me it made a huge difference in my treatment when I finally knew the diagnosis. And I am certain
that I wouldn’t be as well as I still am when I would have continued in the way as I did before it.
[Participant 011, adult, positive PCD]
C She was sick every month. Once we had a diagnosis … she gets sick, but not as severe as … before.
Definitely milder … you know we have a treatment plan and even when she starts to get sick; those
medications are changed so we tend to catch that right away rather than after that. [Participant 015,
parent, positive PCD]
D It’s strange, since being diagnosed we are now bombarded with a very heavy burden of care, she uses
the nebulisers three times a day, and she has physio twice a day … and yet she’s not clinically, she’s
no different to before she was diagnosed. [Participant 004, parent, positive PCD]
Support from PCD patient organisations
E Well we go, after the diagnosis … through the PCD Foundation, and that was a huge support. Also
there is like chat groups that we go on. We’ve gone to family days. So we’ve met quite a few other
families that also have PCD … yeah, it’s a huge, huge help really. Sometimes it’s even just finding out
what they did in certain situations. So things you can bring up to your doctor, so that’s helpful as well.
[Participant 015, parent, positive PCD]
F I got connected with the PCD group online … without the people in this group … I would be terribly lost
… they’ve been my life support. [Participant 009, adult patient, positive PCD]
Need for PCD patient organisations in each country
G In Spain, we would like … a Patients Association …, in the UK there will be one of these, you know this
association, but in Spain we don’t know anything about the illness and the patients. [Participant 013,
parent, positive PCD]
H There isn’t any in Ireland … I don’t know anybody else that has it, and if I did know somebody that
would be handy … like you could see … what does the future hold for us in a few years’ time, really
we’re only going day-by-day, and I know every case is different, but it would be nice to kind of know
other issues some people have experienced. And the mistakes I made, maybe you could try this, which
might help. [Participant 003, parent, inconclusive PCD]
I I think it’s difficult. There is no information in Bulgarian for example … and I would speak English so I
can get a lot of information from the internet, but if you are a Bulgarian and you do not speak English,
it’s very, very hard for you to get that information. [Participant 012, adult patient, probable PCD]
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status was uncertain. This inherently means that allocation of patients to diagnostic outcome groups was
defined by the participants’ understanding rather than the diagnosis that might be provided by a highly
specialist centre; this is at the same time a strength and a weakness of the study.
Implications and conclusion
This study concludes that there are a number of recommendations for the improvement of PCD diagnosis
from the patient’s perspective and that are needed across Europe and internationally. 1) Samples should be
analysed by PCD experts. 2) Results should be delivered by a PCD expert. Patients should have the
opportunity to discuss their results with a PCD expert and to ask questions. 3) Repeat testing should be
completed if needed, to ensure an accurate result. 4) Measures must be introduced to prevent late
diagnosis such as better knowledge of PCD by medical practitioners, including relevance of past medical
history. 4) A resolution to the “inconclusive” diagnosis result status. 5) Establishment of a patient support
group in each country. 6) Availability of online translated information on PCD in all European languages
This is the first international study evaluating PCD patients’ experiences and their perspective on the
diagnostic process. The findings from this study will be used to advise the ERS Task Force (TF-2014-04)
as they develop clinical practice guidelines on diagnosing or refuting the diagnosis of PCD. We anticipate
that the results will inform stakeholders with responsibility for improving existing diagnostic provision and
for expanding services for this rare disease. It should feed into the new European Reference Networks
(ERNs) for rare diseases, particularly the PCD ERN.
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